S. Douc‐Rasy

发表

Netrin-1 acts as a survival factor for aggressive neuroblastoma

D. Cappellen, A. Nakagawara, A. Puisieux, 2009, The Journal of experimental medicine.

GALNT9 gene expression is a prognostic marker in neuroblastoma patients.

J. Bénard, E. Osinaga, D. Valteau‐Couanet, 2013, Clinical chemistry.

ATP-independent type II topoisomerase from trypanosomes.

G. Riou, J. Riou, A. Kayser, 1986, Proceedings of the National Academy of Sciences of the United States of America.

MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.

J. Bénard, M. Barrois, S. Léonce, 2003, The American journal of pathology.

(cid:1) N -p73 (cid:1) Accumulates in Human Neuroblastic Tumors

M. Kaghad, D. Caput, U. Moll, 2002 .

Association of c‐erbB2‐gene amplification with poor prognosis in non‐inflammatory breast carcinomas but not in carcinomas of the inflammatory type

J. Ahomadégbé, G. Riou, M. Spielmann, 1994, International journal of cancer.

[Micro-RNA and oncogenesis].

J. Bénard, S. Douc‐Rasy, J. Bénard, 2005, Bulletin du cancer.

ATP‐independent DNA topoisomerase II as potential drug target in trypanosomes

G. Riou, J. Riou, S. Douc-Rasy, 1988, Biology of the cell.

A type I DNA topoisomerase from Trypanosoma cruzi.

G. Riou, M. Barrois, A. Kayser, 1983, European journal of biochemistry.

Inhibitors of trypanosome topoisomerases.

G. Riou, A. Kayser, S. Douc‐Rasy, 1986, Biochemical Society transactions.

A specific inhibitor of type I DNA-topoisomerase of Trypanosoma cruzi: dimethyl-hydroxy-ellipticinium.

G. Riou, A. Kayser, S. Douc‐Rasy, 1983, Biochemical and biophysical research communications.

Inhibition of the reactions catalysed by a type I topoisomerase and catenating enzyme of Trypanosoma cruzi by DNA‐intercalating drugs. Preferential inhibition of the catenating reaction.

G. Riou, A. Kayser, S. Douc-Rasy, 1984, The EMBO journal.

[High incidence of p53 mutations in primary and metastatic head and neck tumors. Frequent protein overexpression in normal epithelium].

J. Armand, G. Riou, M. Barrois, 1996, Bulletin du cancer.

A Ku80 fragment with dominant negative activity imparts a radiosensitive phenotype to CHO-K1 cells.

P. Jeggo, J. Bourhis, J. Bernier, 2000, Nucleic acids research.

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

L. Meijer, J. Endicott, S. Baumli, 2010, Genes & cancer.

Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients

G. Le Teuff, V. Combaret, P. Busson, 2014, Cancer medicine.

Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma

B. Job, P. Dessen, C. Richon, 2011, British Journal of Cancer.

Wnt-5a gene expression in malignant human neuroblasts.

S. Douc-Rasy, G. Raguénez, D. Goldschneider, 2005, Cancer letters.

Expression of C-terminal deleted p53 isoforms in neuroblastoma

E. May, G. Danglot, M. Guillaud-Bataille, 2006, Nucleic acids research.

The neurogene BTG2TIS21/PC3 is transactivated by ΔNp73α via p53 specifically in neuroblastoma cells

E. May, A. Puisieux, H. Haddada, 2005, Journal of Cell Science.

High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.

J. Armand, G. Riou, M. Barrois, 1995, Oncogene.

Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant

E. Ségal-Bendirdjian, S. Bombard, J. Hillion, 2012, Molecular Cancer Therapeutics.

High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19.

G. Riou, M. Barrois, J. Coll, 1996, Oncogene.

TP53 family members and human cancers

S. Douc-Rasy, S. Douc‐Rasy, J. Bénard, 2003, Human mutation.

DeltaN-p73alpha accumulates in human neuroblastic tumors.

M. Kaghad, D. Caput, U. Moll, 2002, The American journal of pathology.

Genomic and allelic expression status of the p73 gene in human neuroblastoma.

D. Caput, M. Barrois, A. Chompret, 2001, Medical and pediatric oncology.

Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line

H. Haddada, M. Barrois, A. Legrand, 2004, Journal of Cell Science.

Differential regulation of p 73 variants in response to cisplatin treatment in SH-SY 5 Y neuroblastoma cells

F. Tournier, K. Million, S. Douc-Rasy, 2022 .

Protein-induced unwinding of DNA: measurement by gel electrophoresis of complexes with DNA minicircles. Application to restriction endonuclease EcoRI, catabolite gene activator protein and lac repressor.

A. Kolb, A. Prunell, S. Douc‐Rasy, 1989, Nucleic Acids Research.

Chromatin reconstitution on small DNA rings. IV. DNA supercoiling and nucleosome sequence preference.

S. Douc-Rasy, I. Duband-Goulet, A. Prunell, 1992, Journal of molecular biology.

Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts

J. Bourhis, J. Bernier, M. Barrois, 2000, Cancer Gene Therapy.

p73α isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells

D. Cappellen, Matthieu Bauer, S. Douc-Rasy, 2008, Nucleic acids research.

When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein.

H. Haddada, S. Douc-Rasy, G. Raguénez, 2003, Cancer letters.

The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.

E. May, A. Puisieux, H. Haddada, 2005, Journal of cell science.